close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PepGen Inc. - Common Stock (NQ:PEPG)

1.730 -0.010 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PepGen Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
PEPG Investors Have Opportunity to Join PepGen Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via Business Wire
News headline image
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
From PepGen Inc.
Via Business Wire
News headline image
PEPG Stock Earnings: PepGen Beats EPS for Q1 2024 ↗
PEPG stock results show that PepGen beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023 ↗
PEPG stock results show that PepGen beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
PepGen Announces Executive Team Promotions
From PepGen Inc.
Via Business Wire
News headline image
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Insiders Buying GameStop And 2 Other Stocks ↗
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
From PepGen Inc.
Via GlobeNewswire
News headline image
Over $37M Bet On This Industrial Stock? Check Out These 4 Stocks Insiders Are Buying ↗
Although U.S. stocks closed sharply lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data
PepGen stock is moving higher on expectations of positive Phase 2 clinical trial results for its Duchenne muscular dystrophy (DMD) gene therapy 
Via MarketBeat
News headline image
Top 4 Health Care Stocks That May Crash This Quarter ↗
As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
News headline image
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
From PepGen Inc.
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today